ADVFN Logo ADVFN
시장 데이터
뉴스
도구
시장
팔로우

Hot Features

피드 팔로우

Follow Feed 커뮤니티에서 거래자 및 투자자와 연결하세요.

실시간 옵션 플로우

포괄적인 옵션 데이터를 탐색하고 옵션 흐름으로 고급 필터를 사용하세요.

모니터

터미널 모니터로 주식 및 자산 관심 목록을 구성하고 모니터링하세요.
로그인 Premium Icon프리미엄 Help Menu
S&P 500
5,626.02
0.54%
US Tech 100
18,986.40
0.30%
다우존스 지수
41,393.78
0.72%
Bitcoin
59,872.55
-0.23%
Registration Strip Icon for alerts 실시간 알림, 사용자 정의 포트폴리오 및 시장 동향을 받으려면 등록하세요.
등록
  1. 홈
  2. 인베스팅
  3. 주식
  4. 미국
  5. NASDAQ

  6. AN2 Therapeutics Inc (ANTX) 시세

AN2 Therapeutics Inc

AN2 Therapeutics Inc (ANTX)

NASDAQ
1.04
0.00
(0.00%)
마감 16 9월 5:00AM
15분 지연
1.04
0.00
(0.00%)
시간외 거래: 5:22AM
15분 지연

포트폴리오 강화: 실시간 토론 및 실행 가능한 거래 아이디어.

프리미엄

주요 통계 및 세부정보

가격
1.04
매수가
1.01
매도가
1.05
거래량
211,853
1.02 일간 변동폭 1.06
0.87 52주 범위 23.58
market_cap
31.036M
전일 종가
1.04
개장가
1.058
최근 거래 시간
3558
@
1.04
마지막 거래 시간
재정 규모
US$ 219,691
VWAP
1.037
평균 볼륨(3m)
425,669
발행 주식
29,842,431
배당수익률
-
주가수익률
-0.48
주당순이익(EPS)
-2.17
매출
-
순이익
-64.73M

AN2 Therapeutics Inc 정보

AN2 Therapeutics Inc is a clinical-stage biopharmaceutical company developing treatments for rare, chronic, and serious infectious diseases with high unmet needs. The initial product candidate is epetraborole, a once-daily oral treatment for patients with chronic non-tuberculous mycobacterial, or NT... AN2 Therapeutics Inc is a clinical-stage biopharmaceutical company developing treatments for rare, chronic, and serious infectious diseases with high unmet needs. The initial product candidate is epetraborole, a once-daily oral treatment for patients with chronic non-tuberculous mycobacterial, or NTM, lung disease. 더 보기

섹터
Pharmaceutical Preparations
산업
Pharmaceutical Preparations
웹사이트
www.an2therapeutics.com
본부
Dover, Delaware, USA
설립됨
-
AN2 Therapeutics Inc is listed in the Pharmaceutical Preparations sector of the 나스닥 with ticker ANTX. The last closing price for AN2 Therapeutics was US$1.04. Over the last year, AN2 Therapeutics shares have traded in a share price range of US$ 0.87 to US$ 23.58.

AN2 Therapeutics currently has 29,842,431 shares in issue. The market capitalisation of AN2 Therapeutics is US$31.04 million. AN2 Therapeutics has a price to earnings ratio (PE ratio) of -0.48.

ANTX 최신 뉴스

추가 뉴스

AN2 Therapeutics to Present at the H.C. Wainwright 26th Annual Global Investment Conference

AN2 Therapeutics, Inc. (Nasdaq: ANTX), a biopharmaceutical company focused on discovering and developing novel small molecule therapeutics derived from its boron chemistry platform, today...

29 8월 2024
Business Wire

Form 8-A12B - Registration of securities [Section 12(b)]

19 8월 2024
Edgar (US Regulatory)

Form 8-K - Current report

19 8월 2024
Edgar (US Regulatory)

AN2 Therapeutics Adopts Limited Duration Stockholder Rights Plan

AN2 Therapeutics, Inc. (Nasdaq: ANTX), a biopharmaceutical company focused on discovering and developing novel small molecule therapeutics derived from its boron chemistry platform, today...

16 8월 2024
Business Wire

Form 10-Q - Quarterly report [Sections 13 or 15(d)]

14 8월 2024
Edgar (US Regulatory)

Form 8-K - Current report

14 8월 2024
Edgar (US Regulatory)

AN2 Therapeutics Reports Second Quarter 2024 Financial Results and Recent Business and Scientific Highlights

Cash, cash equivalents, and investments of $104.5 million at June 30, 2024; cash runway anticipated to fund operations through 2027 AN2 Therapeutics, Inc. (Nasdaq: ANTX), a biopharmaceutical...

14 8월 2024
Business Wire

Form 8-K - Current report

09 8월 2024
Edgar (US Regulatory)

AN2 Therapeutics Provides Update on EBO-301 Phase 2/3 Study Evaluating Epetraborole for Treatment-Refractory Mycobacterium avium Complex (MAC) Lung Disease

EBO-301 study to be discontinued following topline results from Phase 2 part of the study in treatment-refractory patients with MAC lung disease AN2 plans to shift focus to internal boron...

09 8월 2024
Business Wire

Form 4 - Statement of changes in beneficial ownership of securities

13 7월 2024
Edgar (US Regulatory)
기간변동변동 %시가고가저가평균 일일 거래량VWAP
1001.041.190.956533451.07197583CS
4-1.02-49.51456310682.063.070.876415731.25881664CS
12-1.85-64.01384083042.893.880.874256691.74884483CS
26-14.82-93.442622950815.8622.220.873221334.02293737CS
52-15.81-93.827893175116.8523.580.871658165.56677675CS
156-15.81-93.827893175116.8523.580.871658165.56677675CS
2600001.08000CS

이동자

모두 보기
  • 가장 활성
  • % 상승자
  • % 패자
기호가격볼륨
NOVVUNova Vision Acquisition Corporation
US$ 41.00
(207.35%)
17.4k
NOVVNova Vision Acquisition Corporation
US$ 37.0001
(200.08%)
202.75k
SMXSMX Security Matters Public Company
US$ 5.85
(138.78%)
49.72M
OMICSingular Genomics Systems Inc
US$ 12.38
(119.12%)
2.72M
TILInstill Bio Inc
US$ 84.75
(82.41%)
3.76M
GSIWGarden Stage Ltd
US$ 2.9693
(-75.66%)
4.21M
UPCUniverse Pharmaceuticals Inc
US$ 0.55
(-67.07%)
29.83M
VMARVision Marine Technologies Inc
US$ 0.77
(-48.67%)
30.61M
PRLDPrelude Therapeutics Inc
US$ 2.775
(-42.55%)
2.49M
CNEYCN Energy Group Inc
US$ 0.4335
(-37.17%)
4.79M
NVDANVIDIA Corporation
US$ 119.10
(-0.03%)
238.43M
XXII22nd Century Group Inc
US$ 0.3447
(28.00%)
183.73M
IMRXImmuneering Corporation
US$ 2.02
(41.26%)
136.36M
SQQQProShares UltraPro Short QQQ
US$ 8.17
(-1.33%)
127.78M
MULNMullen Automotive Inc
US$ 0.1328
(-20.48%)
120.81M

ANTX Discussion

게시물 보기
Monksdream Monksdream 1 월 전
ANTX new 52 week low
👍️0
Monksdream Monksdream 2 월 전
ANTX under $3
👍️0
eyeownu eyeownu 2 월 전
looking good
👍️0
glenn1919 glenn1919 2 월 전
ANTX..............https://stockcharts.com/h-sc/ui?s=ANTX&p=W&b=5&g=0&id=p86431144783
👍️0
GO4AWILDRIDE GO4AWILDRIDE 5 월 전
FROM 3/28 NEWS:

Cash, cash equivalents, and investments of $134.5 million at December 31, 2023

GO4AWILDRIDE
👍️0
GO4AWILDRIDE GO4AWILDRIDE 5 월 전
THE FOLLOWING FROM THE 3/28 NEWS:

“AN2’s cash position remains strong as we advance our innovative boron-based pipeline. Following the recent meeting of the independent Data Safety Monitoring Board, we continue to believe in the potential of epetraborole to become an important component of the backbone therapy for NTM lung disease,” said Eric Easom, Co-Founder, President and Chief Executive Officer. “Patients enrolled in the epetraborole Phase 2/3 trial in treatment refractory lung disease caused by MAC continue to be dosed while new enrollment in the Phase 3 part of the trial remains paused. Patients in the Phase 2 trial have reached the six-month mark, and we plan to report topline results this summer. Analysis of the baseline patient demographics from the trial show a highly complex and refractory patient population, which we plan to discuss with the FDA in the coming months.”

GO4AWILDRIDE
👍️0
GO4AWILDRIDE GO4AWILDRIDE 5 월 전
Monksdream

Did you read the 3/28 news from the compay?

Seems like the market is looking to chase the price up.

GLTU

GO4AWILDRIDE
👍️0
GO4AWILDRIDE GO4AWILDRIDE 5 월 전
Monksdream

Seems like a nice rebound is starting to occur.

GLTU

GO4AWILDRIDE
👍️0
Monksdream Monksdream 6 월 전
ANTX new 52 week low
👍️0
Monksdream Monksdream 7 월 전
ANTX new 52 week low
👍️0
Monksdream Monksdream 7 월 전
ANTX new 52 week low
👍️0

최근 히스토리

NASDAQ
ANTX
AN2 Therapeutics
Delayed Upgrade Clock
ADVFN Logo
InvestorsHub

대한민국
회사 소개
사업
Popular
앱 받기
App Store
Google Play

도움 및 지원받기: kr-support@advfn.com

ADVFN 서비스 이용은 ADVFN의 이용약관에 동의하는 것입니다 이용약관

© 2024 ADVFN PLC - 모든 권리 보유